23 May 2013
Keywords: clinical, proof-of-concept, rna, dmd, drug, netherlands, leiden
Article | 07 January 2008
The Netherlands' Leiden University Medical Center (LUMC) and Dutch biotechnology firm Prosensa say that positive results from the first
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 January 2008
22 May 2013
© 2013 thepharmaletter.com